Long-term safety and tolerability of bapineuzumab in patients with Alzheimer’s disease in two phase 3 extension studies

BACKGROUND: Immunotherapy with monoclonal antibodies that target amyloid beta has been under investigation as a treatment for patients with Alzheimer’s disease (AD). The 3000 and 3001 phase 3 clinical studies of intravenous bapineuzumab assessed safety and efficacy in patients with mild to moderate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanoiu, Adrian, Pariente, Jérémie, Booth, Kevin, Lobello, Kasia, Luscan, Gerald, Hua, Lisa, Lucas, Prisca, Styren, Scot, Yang, Lingfeng, Li, David, Black, Ronald S., Brashear, H. Robert, McRae, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918115/
https://www.ncbi.nlm.nih.gov/pubmed/27334799
http://dx.doi.org/10.1186/s13195-016-0193-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918115/
https://www.ncbi.nlm.nih.gov/pubmed/27334799
http://dx.doi.org/10.1186/s13195-016-0193-y

Ejemplares similares